Mechanisms of disease: Genetic predictors of response to treatment in brain tumors

Nature Clinical Practice Oncology

Volumn 4, Issue 6, 2007, Pages 362-374

  Collins, V Peter ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUORO 2 METHYL 5 INDOLYLOXY) 6 METHOXY 7 [3 (1 PYRROLIDINYL)PROPOXY]QUINAZOLINE; ALKYLATING AGENT; BEVACIZUMAB; CETUXIMAB; CP 358794; ERLOTINIB; GEFITINIB; GROWTH FACTOR; IMATINIB; LAPATINIB; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROTEIN P53; RAPAMYCIN; RETINOBLASTOMA 1 PROTEIN; RETINOBLASTOMA PROTEIN; SORAFENIB; SUNITINIB; TEMOZOLOMIDE; TEMSIROLIMUS; TIPIFARNIB; TYKER 6; UNCLASSIFIED DRUG; VANDETANIB; VATALANIB;

ASTROCYTOMA; BRAIN TUMOR; CANCER GRADING; CANCER RISK; CANCER SURVIVAL; CARCINOGENESIS; CHROMOSOME LOSS; CLINICAL TRIAL; DISEASE PREDISPOSITION; DRUG RESPONSE; GENE EXPRESSION PROFILING; GENE MUTATION; GENE SILENCING; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; MIXED TUMOR; MOLECULAR GENETICS; MOLECULAR INTERACTION; MULTIPLE CYCLE TREATMENT; OLIGODENDROGLIOMA; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN METHYLATION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ASTROCYTOMA; BRAIN NEOPLASMS; CLINICAL TRIALS; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; GLIOBLASTOMA; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; OLIGODENDROGLIOMA; RETINOBLASTOMA PROTEIN; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEINS;

EID: 34249889900     PISSN: 17434254     EISSN: 17434262     Source Type: Journal    
DOI: 10.1038/ncponc0820     Document Type: Review

References (80)

1. Hegi ME et al. (2005) MGM silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352: 997-1003
2. Carlson RW et al. (2006) NCCN Task Force Report: Adjuvant therapy for breast cancer. J Natl Compr Canc Netw 4 (Suppl 1): S1-S26
3. Tauchi T and Ohyashiki K (2006) The second generation of BCR-ABL tyrosine kinase inhibitors. Int J Hematol 83: 294-300
4. Schwartzbaum JA et al. (2006) Epidemiology and molecular pathology of glioma. Nat Clin Pract Neurol 2: 494-503
5. Corn B et al. (1994). Malignant oligodendroglioma arising after radiation therapy for lymphoma. Med Pediatr Oncol 22: 45-52
6. Rollison DE et al. (2005) Investigation of human brain tumors for the presence of polyomavirus genome sequences by two independent laboratories. Int J Cancer 113: 769-774
7. Kleihues P et al. (1995) Genetic and environmental factors in the etiology of human brain tumors. Toxicol Lett 82-83: 601-605
8. Malmer B et al. (2001) Genetic epidemiology of glioma. Br J Cancer 84: 429-434
9. Kleihues P and Cavenee WK (2000) Pathology and Genetics of Tumours of the Nervous System. Lyon: International Agency for Research on Cancer (series eds Kleihues P and Sobin LH)
10. Breedveld P et al. (2005) The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): Implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. Cancer Res 65: 2577-2582
11. Schinkel AH (1999) P-Glycoprotein, a gatekeeper in the blood-brain barrier. Adv Drug Deliv Rev 36: 179-194
12. Kleihues P and Ohgaki H (1999) Primary and secondary glioblastomas: From concept to clinical diagnosis. Neuro-oncol 1: 44-51
13. McCormack BM et al. (1992) Treatment and survival of low-grade astrocytoma in adults- 1977-1988. Neurosurgery 31: 636-642
14. Vertosick FT Jr et al. (1991) Survival of patients with well-differentiated astrocytomas diagnosed in the era of computed tomography. Neurosurgery 28: 496-501
15. Stupp R et al. (2005) Optimal role of temozolomide in the treatment of malignant gliomas. Curr Neurol Neurosci Rep 5: 198-206
16. Perry A et al. (1999) Clinicopathologic study of 85 similarly treated patients with anaplastic astrocytic tumors: An analysis of DNA content (ploidy), cellular proliferation, and p53 expression. Cancer 86: 672-683
17. Rasheed A et al. (2000) Molecular markers of prognosis in astrocytic tumors. Cancer 94: 2688-2697
18. Smith JS et al. (2001) PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst 93: 1246-1256
19. Ichimura K et al. (2000) Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities. Cancer Res 60: 417-424
20. James CD et al. (1989) Mitotic recombination of chromosome 17 in astrocytomas. Proc Natl Acad Sci USA 86: 2858-2862
21. Koschny R et al. (2002) Comparative genomic hybridization in glioma: A meta-analysis of 509 cases. Cancer Genet Cytogenet 135: 147-159
22. Hermanson M et al. (1992) Platelet-derived growth factor and its receptors in human glioma tissue: Expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res 52: 3213-3219
23. Ekstrand AJ et al. (1991) Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res 51: 2164-2172
24. Ohgaki H and Kleihues P (2005) Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 64: 479-489
25. von Deimling A et al. (2000) Comprehensive allelotype and genetic anaysis of 466 human nervous system tumors. J Neuropathol Exp Neurol 59: 544-558
26. von Deimling A et al. (1994) Loci associated with malignant progression in astrocytomas: A candidate on chromosome 19q. Cancer Res 54: 1397-1401
27. Backlund LM et al. (2005) Mutations in Rb1 pathway-related genes are associated with poor prognosis in anaplastic astrocytomas. Br J Cancer 93: 124-130
28. Ohgaki H et al. (2004) Genetic pathways to glioblastoma: A population-based study. Cancer Res 64: 6892-6899
29. Reifenberger J et al. (1996) Analysis of p53 mutation and epidermal growth factor receptor amplification in recurrent gliomas with malignant progression. J Neurapathol Exp Neurol 55: 822-831
30. Reifenberger G et al. (1993) Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res 53: 2736-2739
31. Riemenschneider MJ et al. (1999) Amplification and overexpression of the MDM4 (MDMX) gene from 1q32 in a subset of malignant gliomas without TP53 mutation or MDM2 amplification. Cancer Res 59: 6091-6096
32. Sherr CJ and McCormick F (2002) The RB and p53 pathways in cancer. Cancer Cell 2: 103-112
33. Schmidt EE et al. (1994) CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res 54: 6321-6324
34. Reifenberger G et al. (1994) Amplification of multiple genes from chromosomal region 12q13-14 in human malignant gliomas: Preliminary mapping of the amplicons shows preferential involvement of CDK4, SAS, and MDM2. Cancer Res 54: 4299-4303
35. Buschges R et al. (1999) Amplification and expression of cyclin D genes (CCND1, CCND2 and CCND3) in human malignant gliomas. Brain Pathol 9: 435-442; discussion 432-433
36. Ichimura K et al. (1996) Human glioblastomas with no alterations of the CDKN2A (p16INK4A, MTS1) and CDK4 genes have frequent mutations of the retinoblastoma gene. Oncogene 13: 1065-1072
37. Ichimura K et al. (2004) Molecular pathogenesis of astrocytic tumours. J Neurooncol 70: 137-160
38. Nakamura M et al. (2001) Promoter hypermethylation of the RB1 gene in glioblastomas. Lab Invest 81: 77-82
39. Biernat W et al. (1997) Alterations of cell cycle regulatory genes in primary (de novo) and secondary glioblastomas. Acta Neuropathol (Berl) 94: 303-309
40. Libermann TA et al. (1985) Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature 313: 144-147
41. Liu L et al. (2005) Clinical significance of EGFR amplification and the aberrant EGFRvii transcript in conventionally treated astrocytic gliomas. J Mol Med 83: 917-926
42. Okada Y et al. (2003) Selection pressures of TP53 mutation and microenvironmental location influence epidermal growth factor receptor gene amplification in human glioblastomas. Cancer Res 63: 413-416
43. Liu L et al. (2000) The complexity of the 7p12 amplicon in human astrocytic gliomas: Detailed mapping of 246 tumors. J Neuropathol Exp Neurol 59: 1087-1093
44. Huang HS et al. (1997) The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J Biol Chem 272: 2927-2935
45. Collins VP (1995) Gene amplification in human gliomas. Glia 15: 289-296
46. Fleming TP et al. (1992) Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors. Cancer Res 52: 4550-4553
47. Knobbe CB et al. (2004) Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas. Acta Neuropathol (Berl 108: 467-470
48. Steck PA et al. (1997) Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 15: 356-362
49. Schmidt E et al. (1999) Mutational profile of the PTEN/MMAC1 gene in primary human astrocytic tumors and xenografts. J Neuropathol Exp Neurol 58: 1170-1183
50. Knobbe CB and Reifenberger G (2003) Genetic alterations and aberrant expression of genes related to the phosphatidyl-inositol-3′-kinase/ protein kinase B (Akt) signal transduction pathway in glioblastomas. Brain Pathol 13: 507-518
51. Samuels Y et al. (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science 304: 554
52. Knobbe CB et al. (2005) Genetic alteration and expression of the phosphoinositol-3-kinase/Akt pathway genes PIK3CA and PIKE in human glioblastomas. Neuropathol Appl Neurobiol 31: 486-490
53. Knobbe CV et al. (2004) Hypermethylation and transcriptional downregulation of the carboxyl-terminal modulator protein gene in glioblastomas. J Natl Cancer Inst 96: 483-486
54. Rubio-Viqueira B and Hidalgo M (2006) Targeting mTOR for cancer treatment. Curr Opin Investig Drugs 7: 501-512
55. Backlund LM et al. (2003) Short postoperative survival for glioblastoma patients with a dysfunctional Rb1 pathway in combination with no wild-type PTEN. Clin Cancer Res 9: 4151-4158
56. Tso CL et al. (2006) Distinct transcription profiles of primary and secondary glioblastoma subgroups. Cancer Res 66: 159-167
57. Phillips HS et al. (2006) Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9: 157-173
58. Cairncross JG and Macdonald DR (1988) Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol 23: 360-364
59. Reifenberger J et al. (1994) Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol 145: 1175-1190
60. Griffin CA et al. (2006) Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss. J Neuropathol Exp Neurol 65: 988-994
61. Jenkins RB et al. (2006) At(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 66: 9852-9861
62. Cairncross JG et al. (1998) Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90: 1473-1479
63. Cairncross G et al. (2006) Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 24: 2707-2714
64. van den Bent MJ et al. (2006) Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: A randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 24: 2715-2722
65. Mollemann M et al. (2005) Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. Int J Cancer 113: 379-385
66. Idbaih A et al. (2005) Two types of chromosome 1p losses with opposite significance in gliomas. Ann Neurol 58: 483-487
67. Reifenberger G and Louis DN (2003) Oligodendroglioma: Toward molecular definitions in diagnostic neuro-oncology. J Neuropathol Exp Neurol 62: 111-126
68. Wolter M et al. (2001) Oligodendroglial tumors frequently demonstrate hypermethylation of the CDKN2A (MTS1, p16INK4a), p14ARF, and CDKN2B (MTS2, p15INK4b) tumor suppressor genes. J Neuropathol Exp Neurol 60: 1170-1180
69. Cully M et al. (2006) Beyond PTEN mutations: The PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer 6: 184-192
70. Shaw RJ and Cantley LC (2006) Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441: 424-430
71. Yohay KH (2006) The genetic and molecular pathogenesis of NF1 and NF2. Semin Pediatr Neurol 13: 21-26
72. Galiatsatos P and Foulkes WD (2006) Familial adenomatous polyposis. Am J Gastroenterol 101: 385-398
73. Hamilton SR et al. (1995) The molecular basis of Turcot's syndrome. N Engl J Med 332: 839-847
74. Lackner C and Hoefler G (2005) Critical issues in the identification and management of patients with hereditary non-polyposis colorectal cancer. Eur J Gastroenterol Hepatol 17: 317-322
75. Ess KC (2006) The neurobiology of tuberous sclerosis complex. Semin Pediatr Neurol 13: 37-42
76. Inoki K et al. (2005) Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet 37: 19-24
77. Ino Y et al. (2000) Mutation analysis of the hCHK2 gene in primary human malignant gliomas. Neurogenetics 3: 45-46
78. Varley J (2003) TP53, hChk2, and the Li-Fraumeni syndrome. Methods Mol Biol 222: 117-129
79. Sansal I and Sellers WR (2004) The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 22: 2954-2963
80. Greene MH (1999) The genetics of hereditary melanoma and nevi. 1998 update. Cancer 86: 2464-2477